Medication Guide App

Alemtuzumab use while Breastfeeding

Drugs containing Alemtuzumab: Campath

Alemtuzumab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of alemtuzumab during breastfeeding. Because alemtuzumab is a large protein molecule with a molecular weight of 145,454, the amount in milk are likely to be very low and it is not likely to be absorbed by the infant. Until more data become available, alemtuzumab should be avoided during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

Alemtuzumab Identification

Substance Name

Alemtuzumab

CAS Registry Number

216503-57-0

Drug Class

Antineoplastic Agents

Antibodies, Monoclonal, Humanized

Administrative Information

LactMed Record Number

892

Last Revision Date

20130907

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide
(web1)